What is the level of liabilities of Arvinas this year?
Arvinas has a debt balance of 644.6 M USD this year.
Arvinas Liabilities 2024
Arvinas Liabilities
644.6 M USD
Ticker
ARVN
ISIN
US04335A1051
WKN
A2N6VP
In 2024, Arvinas's total liabilities amounted to 644.6 M USD, a -8.42% difference from the 703.9 M USD total liabilities in the previous year.
Arvinas Aktienanalyse
What does Arvinas do?
Arvinas Inc. is a biopharmaceutical company based in New Haven, Connecticut, USA. It was founded in 2013 by Dr. Craig Crews, who also serves as a scientific advisor to the company. The company's mission is to develop innovative therapies based on Proteolysis-Targeting Technology (PROTAC). This technology uses artificially engineered molecules to identify and mark specific proteins in the body, which are then degraded by the body's own enzymes. This approach can treat diseases caused by misfolded or overexpressed proteins. Arvinas' business model is to develop multiple drug candidates based on this platform. The company collaborates with leading academic institutions and biotechnology companies to identify targets that can be reached using PROTAC technology. Additionally, the company has a proprietary pipeline of drug candidates in various stages of clinical development. Arvinas operates in several therapeutic areas, including cancer, immunology, and metabolic disorders. Their drug candidates include ARV-110, a PROTAC targeting the androgen receptor protein (AR), which is a potential therapy for patients with resistant prostate cancer. Similarly, Arvinas' other drug candidates target specific proteins associated with certain diseases. Another drug from the company is ARV-471, an orally administered degrader targeting the estrogen receptor alpha (ERa), which plays a role in breast cancer. ARV-471 is a potential therapy for patients with rare subtypes of breast cancer. Arvinas also has partnerships in various areas of drug development. For example, in collaboration with Pfizer, they are developing ARV-411, a PROTAC targeting the menin-1 protein, which is involved in acute myeloid leukemia. Arvinas also has a partnership with Genentech, a subsidiary of Roche, for the use of PROTAC in the treatment of cancer. Overall, Arvinas is an innovative biopharmaceutical company based on Proteolysis-Targeting Technology, focusing on the development of comprehensive therapeutic approaches. With numerous partnerships and a diverse pipeline, the company is well-positioned to play a significant role in drug development. Arvinas ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Arvinas's Liabilities
Arvinas's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Arvinas's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Arvinas's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Arvinas's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Arvinas’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Arvinas stock
What were the liabilities of Arvinas compared to the previous year?
The liabilities of Arvinas have increased by -8.42% dropped compared to the previous year.
What are the consequences of high debt for investors of Arvinas?
High liabilities can pose a risk for investors of Arvinas, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Arvinas?
Low liabilities mean that Arvinas has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Arvinas affect the company?
An increase in liabilities of Arvinas can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Arvinas affect the company?
A decrease in the liabilities of Arvinas can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Arvinas?
Some factors that can influence the liabilities of Arvinas include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Arvinas so important for investors?
The liabilities of Arvinas are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Arvinas take to modify the liabilities?
To change its liabilities, Arvinas can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Arvinas pay?
Over the past 12 months, Arvinas paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arvinas is expected to pay a dividend of 0 USD.
What is the dividend yield of Arvinas?
The current dividend yield of Arvinas is .
When does Arvinas pay dividends?
Arvinas pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Arvinas?
Arvinas paid dividends every year for the past 0 years.
What is the dividend of Arvinas?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Arvinas located?
Arvinas is assigned to the 'Health' sector.
Wann musste ich die Aktien von Arvinas kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Arvinas from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did Arvinas pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of Arvinas in the year 2023?
In the year 2023, Arvinas distributed 0 USD as dividends.
In which currency does Arvinas pay out the dividend?
The dividends of Arvinas are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Arvinas
Our stock analysis for Arvinas Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arvinas Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
